Literature DB >> 30635448

Is Targeting the Folate Receptor in Ovarian Cancer Coming of Age?

Michael J Birrer1, Ilaria Betella2, Lainie P Martin3, Kathleen N Moore4.   

Abstract

Prognosis for women with epithelial ovarian cancer remains poor. One new molecular target in epithelial ovarian cancer is folate receptor alpha (FRα). This commentary discusses the characteristics that contribute to its attractiveness as a candidate for therapeutic intervention.

Entities:  

Year:  2019        PMID： 30635448      PMCID： PMC6459241          DOI： 10.1634/theoncologist.2018-0459

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


  27 in total

1.  IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.

Authors:  Olga Ab; Kathleen R Whiteman; Laura M Bartle; Xiuxia Sun; Rajeeva Singh; Daniel Tavares; Alyssa LaBelle; Gillian Payne; Robert J Lutz; Jan Pinkas; Victor S Goldmacher; Thomas Chittenden; John M Lambert
Journal:  Mol Cancer Ther       Date:  2015-04-22       Impact factor: 6.261

2.  PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer.

Authors:  R Wendel Naumann; Robert L Coleman; Robert A Burger; Edward A Sausville; Elzbieta Kutarska; Sharad A Ghamande; Nashat Y Gabrail; Stephen E Depasquale; Elzbieta Nowara; Lucy Gilbert; Robert H Gersh; Michael G Teneriello; Wael A Harb; Panagiotis A Konstantinopoulos; Richard T Penson; James T Symanowski; Chandra D Lovejoy; Christopher P Leamon; David E Morgenstern; Richard A Messmann
Journal:  J Clin Oncol       Date:  2013-10-14       Impact factor: 44.544

Review 3.  A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer.

Authors:  Kathleen N Moore; Lainie P Martin; David M O'Malley; Ursula A Matulonis; Jason A Konner; Ignace Vergote; Jose F Ponte; Michael J Birrer
Journal:  Future Oncol       Date:  2017-11-03       Impact factor: 3.404

4.  Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study.

Authors:  Kathleen N Moore; Lainie P Martin; David M O'Malley; Ursula A Matulonis; Jason A Konner; Raymond P Perez; Todd M Bauer; Rodrigo Ruiz-Soto; Michael J Birrer
Journal:  J Clin Oncol       Date:  2016-12-28       Impact factor: 44.544

5.  Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen.

Authors:  Yelena V Kovtun; Charlene A Audette; Yumei Ye; Hongsheng Xie; Mary F Ruberti; Sara J Phinney; Barbara A Leece; Thomas Chittenden; Walter A Blättler; Victor S Goldmacher
Journal:  Cancer Res       Date:  2006-03-15       Impact factor: 12.701

6.  Exploratory study of 99mTc-EC20 imaging for identifying patients with folate receptor-positive solid tumors.

Authors:  Ronald E Fisher; Barry A Siegel; Steven L Edell; Nelson M Oyesiku; David E Morgenstern; Richard A Messmann; Robert J Amato
Journal:  J Nucl Med       Date:  2008-05-15       Impact factor: 10.057

Review 7.  Imaging the folate receptor on cancer cells with 99mTc-etarfolatide: properties, clinical use, and future potential of folate receptor imaging.

Authors:  Alan H Maurer; Philip Elsinga; Stefano Fanti; Binh Nguyen; Wim J G Oyen; Wolfgang A Weber
Journal:  J Nucl Med       Date:  2014-04-14       Impact factor: 10.057

Review 8.  Targeted drug delivery via folate receptors.

Authors:  Xiaobin Zhao; Hong Li; Robert J Lee
Journal:  Expert Opin Drug Deliv       Date:  2008-03       Impact factor: 6.648

9.  A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess Efficacy and Safety of Weekly Farletuzumab in Combination With Carboplatin and Taxane in Patients With Ovarian Cancer in First Platinum-Sensitive Relapse.

Authors:  Ignace Vergote; Deborah Armstrong; Giovanni Scambia; Michael Teneriello; Jalid Sehouli; Charles Schweizer; Susan C Weil; Aristotelis Bamias; Keiichi Fujiwara; Kazunori Ochiai; Christopher Poole; Vera Gorbunova; Wenquan Wang; Daniel O'Shannessy; Thomas J Herzog
Journal:  J Clin Oncol       Date:  2016-03-21       Impact factor: 44.544

10.  Folate receptor alpha (FRA) expression in breast cancer: identification of a new molecular subtype and association with triple negative disease.

Authors:  Daniel J O'Shannessy; Elizabeth B Somers; Julia Maltzman; Robert Smale; Yao-Shi Fu
Journal:  Springerplus       Date:  2012-09-28
View more
  2 in total

1.  Protein Expression of Folate Receptor Alpha in Adenoid Cystic Carcinoma of the Head and Neck.

Authors:  Gregor Heiduschka; Lukas Kenner; Julia Schnoell; Bernhard J Jank; Lorenz Kadletz-Wanke; Stefan Stoiber; Elisabeth Gurnhofer; Michaela Schlederer
Journal:  Onco Targets Ther       Date:  2022-05-16       Impact factor: 4.345

Review 2.  Advancing antibody-drug conjugates in gynecological malignancies: myth or reality?

Authors:  Marta Nerone; Maria Del Grande; Cristiana Sessa; Ilaria Colombo
Journal:  Explor Target Antitumor Ther       Date:  2022-04-19
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.